Newer Therapies for Osteoporosis: A Systematic Review
Parthajit Das1, Mohit Goyal2, Debaditya Roy3
1Rheumatologist, Department of Rheumatology, Asian Institute of Immunology and Rheumatology, Kolkata, West Bengal, India, Orcid: https://orcid.org/0000-0002-1788-846X, Corresponding Author.
Newer osteoporosis treatments, including anabolic agents like abaloparatide and romosozumab, show significant bone mineral density gains and fracture risk reduction in men and postmenopausal women. These novel therapies offer greater efficacy than older options.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Osteoporosis management faces unmet needs, driving demand for novel therapeutic agents.
- Emerging treatments and targets are crucial for improving patient outcomes in osteoporosis care.
Purpose of the Study:
- To critically appraise the evidence on the efficacy of newer osteoporosis therapies.
- To evaluate the impact of novel agents on bone mineral density and fracture incidence.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) from 2013-2023 across Scopus, Embase, and MEDLINE.
- Analysis of bone mineral density (BMD) changes and fracture reduction (vertebral and nonvertebral).
- Assessment of methodological quality using the Oxford scoring system.
Main Results:
- Eighteen RCTs involving 23,341 participants (22,868 postmenopausal women, 473 men) were included.
- Abaloparatide and romosozumab demonstrated significant BMD gains and fracture risk reduction, outperforming teriparatide.
- Blosozumab showed substantial BMD increases; sequential anabolic-then-antiresorptive therapy was more effective than the reverse.
Conclusions:
- Novel osteoporosis therapies significantly enhance BMD and reduce fracture risk in men and postmenopausal women.
- Newer anabolic agents represent a more efficacious treatment option compared to existing therapies.
More Related Videos
03:56Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
Published on: April 26, 2024
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
